Inhaled Antibiotics Market Report 2026

The inhaled antibiotics market size has grown strongly in recent years. It will grow from $1.66 billion in 2025 to $1.8 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising prevalence of cystic fibrosis, increasing incidence of hospital-acquired pneumonia, growing awareness of targeted drug delivery, clinical evidence supporting improved lung function, availability of established nebulizer technologies.

The inhaled antibiotics market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing antibiotic resistance, growth in chronic respiratory disease population, advancements in inhalation drug delivery devices, expanding access to respiratory care in emerging markets, pipeline development of novel inhaled antibiotics. Major trends in the forecast period include expansion of inhaled antibiotics for cystic fibrosis and chronic respiratory infections, growing adoption of dry powder inhaled antibiotic formulations, increased focus on reducing systemic side effects through targeted pulmonary delivery, rising hospital use of nebulized antibiotics for severe infections, development of broad-spectrum inhaled antibiotics for drug-resistant pathogens.

The growing demand in hospitals is expected to drive the expansion of the inhaled antibiotics market. Hospitals are healthcare facilities designed to provide medical treatment, care, and services to individuals who are sick or injured. Inhaled antibiotics are commonly used in hospital settings, especially for treating respiratory infections, as they help minimize the impact on the gut microbiota, tailor treatment plans, improve patient compliance, and reduce hospitalization rates. For example, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the United States had 6,129 hospitals, marking a 0.591% increase from the previous year, which had 6,093 hospitals. Thus, the rising demand in hospitals is contributing to the growth of the inhaled antibiotics market.

Major companies in the inhaled antibiotics market are focusing on innovative products, such as Breyna, to drive revenue growth. Breyna is an inhalation aerosol that contains formoterol fumarate dihydrate and budesonide, designed to manage and prevent symptoms like wheezing and shortness of breath caused by asthma or chronic lung diseases. For example, in July 2023, Viatris Inc., a US-based pharmaceutical company, partnered with Kindeva Drug Delivery L.P., a US company specializing in drug delivery technologies, to launch Breyna. This combination product contains budesonide and formoterol, supplied as a metered-dose inhaler. Breyna is available in two strengths: 80mcg/4.5mcg and 160mcg/4.5mcg. The U.S. Food and Drug Administration (FDA) has approved Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, marking it as the first generic version of AstraZeneca's Symbicort.

In January 2024, Essential Pharma, a UK-based pharmaceutical company, acquired Colobreathe from Teva Laboratories UK Limited for an undisclosed amount. This acquisition marks Essential Pharma's entry into the rare disease sector, expanding its portfolio with treatments for chronic Pseudomonas aeruginosa infections in cystic fibrosis patients. The company aims to ensure ongoing access to essential medicines across Europe through this deal. Teva Laboratories UK Limited is a UK-based manufacturer of inhaled antibiotics.

Major companies operating in the inhaled antibiotics market are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Novartis AG, Bayer AG, Pfizer Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals.

North America was the largest region in the inhaled antibiotics market share in 2025. The regions covered in the inhaled antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaled antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the inhaled antibiotics market by increasing costs for imported active pharmaceutical ingredients, inhalation devices, and precision manufacturing equipment, leading to higher production expenses and pricing pressure for aerosol and dry powder formulations. hospitals and pneumonia-related applications are most affected due to reliance on imported nebulizers and antibiotic solutions, while regions such as asia-pacific and parts of europe face greater supply chain disruptions. however, tariffs are also encouraging local manufacturing, regional api sourcing, and investments in domestic inhalation drug production, supporting long-term supply resilience and localized growth opportunities.

The inhaled antibiotics market research report is one of a series of new reports that provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with a inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inhaled antibiotics are medications designed to treat respiratory-related issues. These antibiotics have improved survival rates and are used to enhance lung function, slow the decline in lung function, extend the time between exacerbations, and improve overall quality of life.

The primary types of inhaled antibiotics include aerosol or metered-dose inhalers, dry powder formulations, sprays, and other forms. A metered-dose inhaler (MDI) is a commonly used device for delivering inhaled respiratory drugs. These inhaled antibiotics are applied in the treatment of conditions such as pneumonia, asthma, bronchitis, and more, with primary use in hospitals and other healthcare settings.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.